Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Int.biotech. (IBT) Share Price

Price 964.00p on 20-01-2026 at 18:55:12
Change 4.00p 0.42%
Buy 964.00p
Sell 954.00p
Last Trade: Buy 5,265.00 at 964.00p
Day's Volume: 82,263
Last Close: 964.00p
Open: 950.00p
ISIN: GB0004559349
Day's Range 942.00p - 964.00p
52wk Range: 480.00p - 1,000.00p
Market Capitalisation: £307.54m
VWAP: 954.43679p
Shares in Issue: 31.90m

Int.biotech. (IBT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 5,265 964.00p Ordinary
16:36:09 - 20-Jan-26
Buy* 2,079 961.744p Ordinary
16:28:30 - 20-Jan-26
Buy* 36 961.752p Ordinary
16:27:28 - 20-Jan-26
Sell* 435 956.00p Automatic Execution
16:22:54 - 20-Jan-26
Unknown* 2,151 960.00p SI Trade
16:22:46 - 20-Jan-26
Buy* 750 960.00p Automatic Execution
16:22:46 - 20-Jan-26
Sell* 904 956.9441p Ordinary
16:20:08 - 20-Jan-26
Sell* 88 954.00p Automatic Execution
16:18:36 - 20-Jan-26
Sell* 44 956.00p Automatic Execution
16:18:36 - 20-Jan-26
Sell* 5,459 956.08p Ordinary
16:18:12 - 20-Jan-26
See more Int.biotech. trades

Int.biotech. (IBT) Share Price History

Time period:
to
Date Open High Low Close Volume
20th Jan 2026 (Tue) 950.00 964.00 942.00 964.00 82,263
19th Jan 2026 (Mon) 960.00 964.00 952.00 960.00 103,581
16th Jan 2026 (Fri) 966.00 974.00 964.00 970.00 64,502
15th Jan 2026 (Thu) 970.00 986.00 966.00 972.00 67,590
14th Jan 2026 (Wed) 962.00 968.00 956.00 968.00 76,946
13th Jan 2026 (Tue) 964.00 966.00 954.00 954.00 69,060
12th Jan 2026 (Mon) 970.00 976.00 956.00 968.00 85,003
9th Jan 2026 (Fri) 976.00 986.00 968.00 986.00 137,977
8th Jan 2026 (Thu) 974.00 980.00 968.00 968.00 90,166
7th Jan 2026 (Wed) 948.00 972.00 944.00 970.00 111,724
6th Jan 2026 (Tue) 938.00 948.00 930.00 946.00 55,447
5th Jan 2026 (Mon) 984.00 984.00 934.00 934.00 123,356
2nd Jan 2026 (Fri) 980.00 982.00 960.00 966.00 65,561
1st Jan 2026 (Thu) 964.00 964.00 964.00 964.00 0
31st Dec 2025 (Wed) 976.00 982.00 964.00 964.00 28,756
30th Dec 2025 (Tue) 976.00 982.00 960.00 960.00 38,384
29th Dec 2025 (Mon) 974.00 984.00 966.00 972.00 49,148
26th Dec 2025 (Fri) 980.00 980.00 980.00 980.00 0
25th Dec 2025 (Thu) 980.00 980.00 980.00 980.00 0
24th Dec 2025 (Wed) 990.00 990.00 978.00 980.00 42,795
23rd Dec 2025 (Tue) 984.00 990.00 980.00 980.00 43,671
22nd Dec 2025 (Mon) 970.00 990.00 966.00 990.00 43,138
See more Int.biotech. price history

Int.biotech. (IBT) Regulatory News

Date Source Headline
19th Jan 2026 12:00 pm RNS Net Asset Value(s)
16th Jan 2026 11:17 am RNS Net Asset Value(s)
15th Jan 2026 11:56 am RNS Net Asset Value(s)
14th Jan 2026 11:52 am RNS Net Asset Value(s)
13th Jan 2026 11:20 am RNS Net Asset Value(s)
12th Jan 2026 11:58 am RNS Net Asset Value(s)
9th Jan 2026 11:57 am RNS Net Asset Value(s)
8th Jan 2026 11:59 am RNS Net Asset Value(s)
7th Jan 2026 11:37 am RNS Net Asset Value(s)
6th Jan 2026 11:24 am RNS Net Asset Value(s)
See more Int.biotech. regulatory news

Int.biotech. (IBT) Share News

UK dividends calendar - next 7 days

16th Jan 2026 15:52

Read More

UK dividends calendar - next 7 days

22nd Dec 2025 14:43

Read More

International Biotechnology beats benchmark with 0.7% NAV gain

6th Nov 2025 19:17

(Alliance News) - International Biotechnology Trust PLC on Thursday said its portfolio continued to outperform the sector benchmark as the company reported full-year results. Read More

IN BRIEF: International Biotechnology Trust notes Novo to buy Akero

9th Oct 2025 15:40

International Biotechnology Trust PLC - investor in biotech and life science companies - Notes portfolio firm Akero Therapeutics Inc as agreed to be taken over by Novo Nordisk AS in a deal worth up to EUR5.2 billion. Novo Nordisk will pay an initial USD54 per share, with a contingent portion of the deal worth USD6 per share. The Bagsvaerd, Denmark-based pharmaceuticals company will pay an initial EUR4.7 billion to buy the firm, and a potential additional payment of EUR500 million, hinging on US regulatory approval for key Akero treatment Efruxifermin. The deal adds Akero's Efruxifermin to Novo Nordisk's portfolio. The asset is aimed at treating metabolic dysfunction-associated steatohepatitis, a disease caused by fat buildup in the liver. Read More

International Biotechnology to raise unquoted exposure with Schroders

2nd Oct 2025 13:31

(Alliance News) - International Biotechnology Trust PLC on Thursday said it has partnered with Schroders Capital to access more investees in the earlier stages of development. Read More

See more Int.biotech. news
FTSE 100 Latest
Value10,126.78
Change-68.57

Login to your account

Forgot Password?

Not Registered